{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:07:34Z","timestamp":1774588054634,"version":"3.50.1"},"reference-count":102,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.soc.2025.10.004","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T21:07:22Z","timestamp":1768424842000},"page":"251-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disrupting the Immunosuppressive Myeloid Compartment in Solid Tumors"],"prefix":"10.1016","volume":"35","author":[{"given":"Manan","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Van der Jeught","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jashodeep","family":"Datta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.soc.2025.10.004_bib1","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.soc.2025.10.004_bib2","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"issue":"26","key":"10.1016\/j.soc.2025.10.004_bib3","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.soc.2025.10.004_bib4","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.gastha.2023.09.007","article-title":"Colorectal cancer immunotherapy: state of the art and future directions","volume":"2","author":"Cornista","year":"2023","journal-title":"Gastro Hep Advances"},{"issue":"1","key":"10.1016\/j.soc.2025.10.004_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","article-title":"Myeloid immunosuppression and immune checkpoints in the tumor microenvironment","volume":"17","author":"Nakamura","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"10.1016\/j.soc.2025.10.004_bib6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.soc.2025.10.004_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun"},{"issue":"6024","key":"10.1016\/j.soc.2025.10.004_bib8","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"issue":"237","key":"10.1016\/j.soc.2025.10.004_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.soc.2025.10.004_bib10","doi-asserted-by":"crossref","unstructured":"Osorio JC, Knorr DA, Weitzenfeld P, et al. Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell. https:\/\/doi.org\/10.1016\/j.ccell.2025.07.013.","DOI":"10.1016\/j.ccell.2025.07.013"},{"issue":"6774","key":"10.1016\/j.soc.2025.10.004_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/35004599","article-title":"A clonogenic common myeloid progenitor that gives rise to all myeloid lineages","volume":"404","author":"Akashi","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.soc.2025.10.004_bib12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev-immunol-042718-041728","article-title":"The myeloid cell compartment-cell by cell","volume":"37","author":"Bassler","year":"2019","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"10.1016\/j.soc.2025.10.004_bib13","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","article-title":"Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses","volume":"73","author":"Mitchem","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.soc.2025.10.004_bib14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.celrep.2017.03.037","article-title":"Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis","volume":"19","author":"Tsujikawa","year":"2017","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.soc.2025.10.004_bib15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrc.2016.54","article-title":"The role of myeloid cells in cancer therapies","volume":"16","author":"Engblom","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.soc.2025.10.004_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.immuni.2017.07.014","article-title":"Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression","volume":"47","author":"Zhu","year":"2017","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.soc.2025.10.004_bib17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/cgt.2016.65","article-title":"Myeloid-derived suppressor cells and their role in pancreatic cancer","volume":"24","author":"Pergamo","year":"2017","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"10.1016\/j.soc.2025.10.004_bib18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1513\/pats.200603-078AW","article-title":"Neutrophil elastase","volume":"3","author":"Chua","year":"2006","journal-title":"Proc Am Thorac Soc"},{"issue":"6409","key":"10.1016\/j.soc.2025.10.004_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/science.aao4227","article-title":"Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice","volume":"361","author":"Albrengues","year":"2018","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.soc.2025.10.004_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/intimm\/dxs004","article-title":"Arginine deficiency leads to impaired cofilin dephosphorylation in activated human T lymphocytes","volume":"24","author":"Feldmeyer","year":"2012","journal-title":"Int Immunol"},{"key":"10.1016\/j.soc.2025.10.004_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101891","article-title":"Immune cell - produced ROS and their impact on tumor growth and metastasis","volume":"42","author":"Kennel","year":"2021","journal-title":"Redox Biol"},{"key":"10.1016\/j.soc.2025.10.004_bib22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcdb.2017.05.023","article-title":"ROS signalling in the biology of cancer","volume":"80","author":"Moloney","year":"2018","journal-title":"Semin Cell Dev Biol"},{"issue":"6","key":"10.1016\/j.soc.2025.10.004_bib23","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ccell.2017.11.004","article-title":"Myeloid cell-derived reactive oxygen species induce epithelial mutagenesis","volume":"32","author":"Canli","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.soc.2025.10.004_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ccell.2016.06.001","article-title":"Origin and role of a subset of tumor-associated neutrophils with antigen-presenting cell features in early-stage human lung cancer","volume":"30","author":"Singhal","year":"2016","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.soc.2025.10.004_bib25","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1016\/j.cell.2021.04.016","article-title":"Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis","volume":"184","author":"Cui","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.soc.2025.10.004_bib26","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-24-3914","article-title":"Lipid nanoparticle-encapsulated mRNAs encoding tumor-specific toxin proteins selectively target cancer cells and stimulate t cell infiltration","author":"Zhou","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.soc.2025.10.004_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.smim.2018.02.001","article-title":"Mast cells, basophils and eosinophils: from allergy to cancer","volume":"35","author":"Rigoni","year":"2018","journal-title":"Semin Immunol"},{"issue":"12","key":"10.1016\/j.soc.2025.10.004_bib28","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic cells and cancer immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1016\/j.soc.2025.10.004_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40425-019-0565-5","article-title":"Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen","volume":"7","author":"Wculek","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.soc.2025.10.004_bib30","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"issue":"7802","key":"10.1016\/j.soc.2025.10.004_bib31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.soc.2025.10.004_bib32","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1158\/1078-0432.CCR-13-0525","article-title":"Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2\/CCR2 axis","volume":"19","author":"Sanford","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.soc.2025.10.004_bib33","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"issue":"7355","key":"10.1016\/j.soc.2025.10.004_bib34","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.soc.2025.10.004_bib35","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1158\/2159-8290.CD-22-1046","article-title":"Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer","volume":"13","author":"Bianchi","year":"2023","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.soc.2025.10.004_bib36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41577-022-00737-w","article-title":"Myeloid cell-targeted therapies for solid tumours","volume":"23","author":"Goswami","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.soc.2025.10.004_bib37","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.soc.2025.10.004_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000330095","article-title":"S100A8 and S100A9: new insights into their roles in malignancy","volume":"4","author":"Srikrishna","year":"2012","journal-title":"J Innate Immun"},{"issue":"27","key":"10.1016\/j.soc.2025.10.004_bib39","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody\u2013mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc Natl Acad Sci"},{"issue":"17","key":"10.1016\/j.soc.2025.10.004_bib40","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc Natl Acad Sci"},{"issue":"16_suppl","key":"10.1016\/j.soc.2025.10.004_bib41","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.11508","article-title":"Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: results from the low-dose expansion cohort","volume":"41","author":"Movva","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.soc.2025.10.004_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.2517","article-title":"First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies","volume":"39","author":"Roohullah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7769","key":"10.1016\/j.soc.2025.10.004_bib43","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.soc.2025.10.004_bib44","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136073","article-title":"ST2 as checkpoint target for colorectal cancer immunotherapy","volume":"5","author":"Van der Jeught","year":"2020","journal-title":"JCI Insight"},{"issue":"2_Supplement","key":"10.1016\/j.soc.2025.10.004_bib45","doi-asserted-by":"crossref","first-page":"C002","DOI":"10.1158\/1538-7445.PANCA2023-C002","article-title":"Abstract C002: interleukin-1 receptor accessory protein (IL1RAP) overexpression is associated with worse prognosis in PDAC and is targetable by nadunolimab","volume":"84","author":"Van Cutsem","year":"2024","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.soc.2025.10.004_bib46","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1158\/1078-0432.CCR-24-0645","article-title":"Efficacy and safety of the Anti-IL1RAP antibody nadunolimab (CAN04) in combination with gemcitabine and nab-paclitaxel in patients with advanced\/metastatic pancreatic cancer","volume":"30","author":"Van Cutsem","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.soc.2025.10.004_bib47","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.soc.2025.10.004_bib48","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.4049\/jimmunol.1101225","article-title":"Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells","volume":"187","author":"Ryzhov","year":"2011","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.soc.2025.10.004_bib49","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1189\/jlb.0113043","article-title":"Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages","volume":"94","author":"Koscs\u00f3","year":"2013","journal-title":"J Leukoc Biol"},{"issue":"20","key":"10.1016\/j.soc.2025.10.004_bib50","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-13-0545","article-title":"Targeting CD73 enhances the antitumor activity of Anti-PD-1 and Anti-CTLA-4 mAbs","volume":"19","author":"Allard","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.soc.2025.10.004_bib51","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41388-021-02132-6","article-title":"CD73 induces GM-CSF\/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis","volume":"41","author":"King","year":"2022","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.soc.2025.10.004_bib52","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41416-024-02796-3","article-title":"COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer","volume":"131","author":"Segal","year":"2024","journal-title":"Br J Cancer"},{"issue":"29","key":"10.1016\/j.soc.2025.10.004_bib53","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1080\/14796694.2024.2354160","article-title":"PACIFIC-9: phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer","volume":"20","author":"Barlesi","year":"2024","journal-title":"Future Oncol"},{"issue":"20","key":"10.1016\/j.soc.2025.10.004_bib54","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1158\/1078-0432.CCR-24-0499","article-title":"A phase Ib\/II randomized clinical trial of oleclumab with or without durvalumab plus chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma","volume":"30","author":"Coveler","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"17_Supplement_2","key":"10.1016\/j.soc.2025.10.004_bib55","doi-asserted-by":"crossref","first-page":"C007","DOI":"10.1158\/1538-7445.PANCREATIC24-C007","article-title":"Abstract C007: quemliclustat (CD73 Inhibitor) reduces adenosine-regulated NR4A gene expression and increases mPDAC inflammation in patients from the ARC-8 trial","volume":"84","author":"Kim","year":"2024","journal-title":"Cancer Res"},{"issue":"Supplement_1","key":"10.1016\/j.soc.2025.10.004_bib56","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1093\/oncolo\/oyad216.022","article-title":"Phase 1b\/2 trial of ipilimumab, nivolumab, and ciforadenant (INC) (Adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma","volume":"28","author":"Beckermann","year":"2023","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.soc.2025.10.004_bib57","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.soc.2025.10.004_bib58","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","article-title":"First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors","volume":"72","author":"Bendell","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"16_suppl","key":"10.1016\/j.soc.2025.10.004_bib59","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS11594","article-title":"A phase II multi-arm study to test the efficacy of oleclumab and durvalumab in specific sarcoma subtypes","volume":"40","author":"Somaiah","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2025.10.004_bib60","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol"},{"issue":"32","key":"10.1016\/j.soc.2025.10.004_bib61","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.soc.2025.10.004_bib62","doi-asserted-by":"crossref","first-page":"905-e848","DOI":"10.1093\/oncolo\/oyac174","article-title":"Epacadostat plus pembrolizumab and chemotherapy for advanced solid tumors: results from the phase I\/II ECHO-207\/KEYNOTE-723 study","volume":"27","author":"Powderly","year":"2022","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.soc.2025.10.004_bib63","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.soc.2025.10.004_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109233","article-title":"Combination of apatinib with apo-IDO1 inhibitor for the treatment of colorectal cancer","volume":"112","author":"Yu","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"10.1016\/j.soc.2025.10.004_bib65","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1158\/1078-0432.CCR-24-0439","article-title":"Phase 1\/2 study of the indoleamine 2,3-Dioxygenase 1 inhibitor linrodostat mesylate combined with nivolumab or nivolumab and ipilimumab in advanced solid tumors or hematologic malignancies","volume":"31","author":"Luke","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.soc.2025.10.004_bib66","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-16-0064","article-title":"PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo","volume":"22","author":"Niessner","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"32","key":"10.1016\/j.soc.2025.10.004_bib67","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc Natl Acad Sci"},{"issue":"17","key":"10.1016\/j.soc.2025.10.004_bib68","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.soc.2025.10.004_bib69","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.1014","article-title":"Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC)","volume":"38","author":"O'Shaughnessy","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.soc.2025.10.004_bib70","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-20-3305","article-title":"Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with Anti\u2013PD-(L)1 therapy","volume":"27","author":"Hellmann","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.soc.2025.10.004_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102971","article-title":"Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE","volume":"9","author":"Cartwright","year":"2024","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.soc.2025.10.004_bib72","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/cgt.2014.2","article-title":"CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes","volume":"21","author":"Liljenfeldt","year":"2014","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"10.1016\/j.soc.2025.10.004_bib73","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000500359","article-title":"Predicted markers of overall survival in pancreatic cancer patients receiving dendritic cell vaccinations targeting WT1","volume":"97","author":"Ito","year":"2019","journal-title":"Oncology"},{"issue":"71","key":"10.1016\/j.soc.2025.10.004_bib74","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"issue":"7","key":"10.1016\/j.soc.2025.10.004_bib75","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a Novel CD40 agonist monoclonal antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.10.004_bib76","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23033","article-title":"Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors","volume":"2","author":"Vonderheide","year":"2013","journal-title":"OncoImmunology"},{"issue":"12","key":"10.1016\/j.soc.2025.10.004_bib77","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1093\/annonc\/mdv387","article-title":"A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma","volume":"26","author":"Nowak","year":"2015","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.soc.2025.10.004_bib78","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1158\/1078-0432.CCR-13-1320","article-title":"A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma","volume":"19","author":"Beatty","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.soc.2025.10.004_bib79","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.soc.2025.10.004_bib80","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S1470-2045(20)30724-5","article-title":"APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinoma","volume":"22","author":"Reni","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.10.004_bib81","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O'Hara","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.soc.2025.10.004_bib82","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.soc.2025.10.004_bib83","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1158\/2767-9764.CRC-24-0513","article-title":"A phase 2 study of sotigalimab, a CD40 agonist antibody, plus concurrent chemoradiation as neoadjuvant therapy for esophageal and gastroesophageal junction cancers","volume":"5","author":"Ko","year":"2025","journal-title":"Cancer Res Commun"},{"issue":"Suppl 2","key":"10.1016\/j.soc.2025.10.004_bib84","article-title":"596 results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab","volume":"10","author":"Sanborn","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.soc.2025.10.004_bib85","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1468956","article-title":"Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma","volume":"7","author":"Bajor","year":"2018","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.soc.2025.10.004_bib86","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/1078-0432.CCR-23-0475","article-title":"A phase II trial of the CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on Anti-PD-1 therapy","volume":"30","author":"Weiss","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.soc.2025.10.004_bib87","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/s41467-017-01572-7","article-title":"Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain","volume":"8","author":"Singh","year":"2017","journal-title":"Nat Commun"},{"issue":"18","key":"10.1016\/j.soc.2025.10.004_bib88","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93397","article-title":"Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer","volume":"2","author":"Sato-Kaneko","year":"2017","journal-title":"JCI Insight"},{"issue":"46","key":"10.1016\/j.soc.2025.10.004_bib89","doi-asserted-by":"crossref","first-page":"E7240","DOI":"10.1073\/pnas.1608555113","article-title":"Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells","volume":"113","author":"Wang","year":"2016","journal-title":"Proc Natl Acad Sci"},{"issue":"16_suppl","key":"10.1016\/j.soc.2025.10.004_bib90","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.2564","article-title":"Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: a phase I trial","volume":"41","author":"Nardo","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.soc.2025.10.004_bib91","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1078-0432.CCR-21-1411","article-title":"Intralesional SD-101 in combination with pembrolizumab in Anti-PD-1 treatment-na\u00efve head and neck squamous cell carcinoma: results from a multicenter, phase II trial","volume":"28","author":"Cohen","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.soc.2025.10.004_bib92","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153902","article-title":"Irreversible electroporation and nivolumab combined with intratumoral administration of a toll-like receptor ligand, as a means of in vivo vaccination for metastatic pancreatic ductal adenocarcinoma (PANFIRE-III). A Phase-I study protocol","volume":"13","author":"Geboers","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.soc.2025.10.004_bib93","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1158\/1078-0432.CCR-07-4467","article-title":"Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells","volume":"14","author":"Chochi","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.soc.2025.10.004_bib94","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.molimm.2007.01.022","article-title":"TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance","volume":"44","author":"He","year":"2007","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/j.soc.2025.10.004_bib95","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40425-019-0573-5","article-title":"STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models","volume":"7","author":"Jing","year":"2019","journal-title":"J Immunoth Cancer"},{"issue":"7","key":"10.1016\/j.soc.2025.10.004_bib96","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1084\/jem.20061845","article-title":"The chemotherapeutic agent DMXAA potently and specifically activates the TBK1\u2013IRF-3 signaling axis","volume":"204","author":"Roberts","year":"2007","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.soc.2025.10.004_bib97","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-21-1963","article-title":"Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.soc.2025.10.004_bib98","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy424.015","article-title":"Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas","volume":"29","author":"Harrington","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soc.2025.10.004_bib99","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-24-3630","article-title":"Phase I and II clinical studies of the STING agonist ulevostinag with and without pembrolizumab in participants with advanced or metastatic solid tumors or lymphomas","author":"Harrington","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.soc.2025.10.004_bib100","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/vaccines13040371","article-title":"Progress update on STING agonists as vaccine adjuvants","volume":"13","author":"Shen","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.soc.2025.10.004_bib101","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jconrel.2022.03.054","article-title":"Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy","volume":"345","author":"Doshi","year":"2022","journal-title":"J Contr Release"},{"key":"10.1016\/j.soc.2025.10.004_bib102","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jconrel.2024.01.048","article-title":"STING agonist-based hydrogel enhances immune activation in synergy with radiofrequency ablation for hepatocellular carcinoma treatment","volume":"369","author":"Ao","year":"2024","journal-title":"J Contr Release"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:01:01Z","timestamp":1774580461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320725000882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":102,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1055320725000882"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2025.10.004","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disrupting the Immunosuppressive Myeloid Compartment in Solid Tumors","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2025.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}